Peptide LocalCompare price, evidence & access
Search /Compare vendors
Locations/India/Survodutide
Purchase and availability checkSurvodutide in India

Can you buy Survodutide in India?

This page does not establish a legitimate retail purchase from the compound name or an online listing alone. Survodutide is an investigational clinical program.

Direct answers →Open official records →Open the interactive status check
Evidence lane
Investigational clinical program
Destination
India
Source records
3
Reviewed
24 July 2026
ByPeptide Local Editorial DeskUpdated 24 July 2026How we review
Direct answers

What this exact search can and cannot establish.

Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.

01

Can you buy Survodutide in India?

This page does not establish a legitimate retail purchase from the compound name or an online listing alone. Survodutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below. Before acting on an offer, match the exact product, authorization, seller identity, and supply route in the official records below.

02

Which official records should be checked for Survodutide in India?

Resolve the exact identity of Survodutide through SYNCHRONIZE-1 Phase 3 study - NCT06066515 from ClinicalTrials.gov. Then search Approved new drugs from Central Drugs Standard Control Organization for the destination product record and Drug and quality alerts from Central Drugs Standard Control Organization for the seller, establishment, or supply route in India. A match in one record does not replace the other two checks.

03

Does an online listing prove Survodutide is authorized or available in India?

No. A page using the name Survodutide, local currency, a domestic delivery claim, or a familiar package image is only a lead. This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status. For India, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.

Live trial footprint

Survodutide clinical trials in India

3 study records currently list 35 locations in this country, including 24 locations individually marked Recruiting.

Registry update: 24 July 2026
Study records
3
Listed locations
35
Recruiting locations
24
Records with local recruiting sites
2
NCT06632444
Study-wide statusRecruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Listed locations
15
Recruiting locations
13
Registry update
2026-07-09
NCT06632457
Study-wide statusRecruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Listed locations
12
Recruiting locations
11
Registry update
2026-07-09
NCT06077864
Study-wide statusCompleted

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Listed locations
8
Recruiting locations
0
Registry update
2026-07-23
Continue the exact comparison

Related country and compound records.

Compare another tracked name in India, or keep Survodutide fixed and change the destination within Asia-Pacific. The identity, product, and seller checks remain separate.

Continue the exact comparison

Survodutide in Asia-Pacific

Survodutide across 42 countries
Identity before availability

A name alone cannot establish a local verdict.

Survodutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.

Primary identity source: SYNCHRONIZE-1 Phase 3 study - NCT06066515 / ClinicalTrials.gov ↗
Three-record verification path

Identity. Product. Seller or supply.

A credible result must keep these separate. The official links answer different questions and should be checked in sequence.

SYNCHRONIZE-1 Phase 3 study - NCT06066515

SYNCHRONIZE-1 Phase 3 study - NCT06066515 is maintained by ClinicalTrials.gov. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open SYNCHRONIZE-1 Phase 3 study - NCT06066515 ↗

Approved new drugs

Approved new drugs is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Approved new drugs ↗

Drug and quality alerts

Drug and quality alerts is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Drug and quality alerts ↗
India / Country guide

India market context.

India's medicine oversight combines central responsibilities with state licensing and enforcement. CDSCO publishes new-drug approvals and quality or spurious-product alerts, but neither list by itself verifies a clinic, pharmacy, imported research listing, or local seller claim.

  • CDSCO's approved new-drug page publishes dated national approval lists, including a 2026 list, and should be checked for the exact product context.
  • The CDSCO alert index separately publishes quality, spurious-product, recall, and related notices that can change the evidence for a named batch or offer.
  • A peptide seller page, laboratory report, or foreign shipping claim is not a substitute for the relevant central product and state establishment records in India.
Destination checklist

Repeat the country checks before comparing any offer.

The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.

01

Check the central approval list

Search CDSCO's approved new-drug records for the exact name and approval period. Do not treat a foreign authorization, sponsor announcement, or ingredient match as an Indian approval entry.

02

Review current quality alerts

Check CDSCO alerts for not-of-standard-quality and spurious batches. An approval record and a later batch alert answer different questions and both may matter.

03

Identify the state record

Pharmacy and sale permissions may depend on the relevant State Drug Control authority, so match the business and jurisdiction instead of assuming a central product entry verifies the seller.

Primary evidence

Audit every source used by this page.

Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.

01
SYNCHRONIZE-1 Phase 3 study - NCT06066515ClinicalTrials.gov
02
Approved new drugsCentral Drugs Standard Control Organization
03
Drug and quality alertsCentral Drugs Standard Control Organization
04
Survodutide study search in IndiaClinicalTrials.gov
05
NCT06632444: LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisClinicalTrials.gov
06
NCT06632457: LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisClinicalTrials.gov
07
NCT06077864: A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)ClinicalTrials.gov
Audit and handoff

Keep the exact record attached.